Heart Failure Flashcards
Acute heart failure
is characterized by a sudden onset of symptoms.
imbalance between oxygen supply and demand and hemodynamic deterioration. Acute heart failure
can be the result of acute myocardial infarction or acute myocarditis, or it can happen as an acute deterioration of chronic heart failure
Chronic heart failure
heart failure that has been adequately treated with appropriate self-management techniques and medical therapies to optimize cardiac output. Not rapidly changing
Sysstolic dysfunction
is the more common type of heart failure. Systolic dysfunction is a problem with pumping
and ventricular emptying and is associated with reduced left ventricular (LV) contractility
and subsequently reduced cardiac output and ejection fraction (EF). The ventricle becomes
large, dilated, congested, and overloaded. Hemodynamically, there is a low cardiac output, an elevated ventricular end-diastolic volume (preload), and an elevated systemic vascular
resistance (afterload).
Dobutamine
Dobutamine is a synthetic catecholamine with mainly beta 1 receptor agonism and some
beta 2 receptor activity, which make Dobutamine an “inotropic vasodilator”
Heart failure
abnormal heart function results in, or increases risk of, clinical symptoms and signs of low cardiac output
Milrinone
phosphodiesterase III inhibitor. Inhibition of phosphodiesterase III results in elevated levels of cyclic adenosine monophosphate in the myocardium and smooth
muscle, which leads to increased cardiac contractility and vasodilation. Milrinone produces
hemodynamic changes similar to those of Dobutamine, but because it works differently, it can be effective if the patient has previously been on beta blockers, a situation where Dobutamine likely will not.
New York Heart Association (NYHA) classification
is a classification system with four levels. Level one ranges from cardiac disease that is
asymptomatic with physical activity to level four, cardiac disease that is symptomatic at
rest.
Self-management strategies for heart failure
daily weight,
dietary management-including fluid and sodium restrictions, exercise
Pharmaceutical
Systolic dysfunction
is the more common type of heart failure. Systolic dysfunction is a problem with pumping
and ventricular emptying and is associated with reduced left ventricular (LV) contractility
and subsequently reduced cardiac output and ejection fraction (EF). The ventricle becomes
large, dilated, congested, and overloaded. Hemodynamically, there is a low cardiac output,
an elevated ventricular end-diastolic volume (preload), and an elevated systemic vascular
resistance (afterload)
Digoxin function in Heart failure
Digoxin acts to enhance inotropy of cardiac muscle and also reduces activation of the SNS and RAAS
DIURETICS function in Heart failure
Diuretics such as furosemide relieve fluid retention (pulmonary congestion and peripheral edema) and improve exercise tolerance
ACE inhibitors function in Heart failure
ACE inhibitors such as captopril and enalapril block the conversion of angiotensin I to angiotensin II, which reduces activation of the RAAS
Angiotensin receptor blockers function in Heart failure
Angiotensin receptor blockers such as valsartan, losartan, and candesartan are used in patients who cannot tolerate ACE inhibitor therapy and work directly on the angiotensin receptors that are the final downstream target of the RAAS pathway
Beta-Blockers function in Heart failure
β-Blocking agents such as carvedilol and metoprolol is used to protect the heart and vasculature from the deleterious effects of overstimulation of the SNS and to help slow the heart down to allow for more efficient contraction
Aldosterone antagonists function in Heart failure
Aldosterone antagonists such as spironolactone also directly inhibit the RAAS
INOTROPES function in Heart failure
Inotropic agents such as milrinone provide direct stimulation of the myocardium to increase contractility.
alveolar gas exchange in heart failure
systolic heart failure (because of the ever increasing preload), blood will eventually “back up” into the lungs and systemic circulation.
In pulmonary edema, the alveolar capillary membrane will be thickened due to the presence of fluid. Thickening of the alveolar capillary membrane results in a reduction of diffusion of gases across the membrane.
V/Q matching.
Shunt- Pulmonary edema
Dead space- Decreased cardiac output
SNS impact in CHF
epinephrine and norepinephrine, catecholamines from the sympathetic nervous system, cause excessive vasoconstriction and an increased afterload
aldosterone causes
salt and water retention and increased preload.
Vasodilators function in Heart failure
The venodilating effects increase venous capacitance and venous pooling, which effectively redistributes fluid and thus reduces preload.
Natriuretic Peptides
because they are produced by the heart in response to atrial and ventricular stretch, and act to offset the sodium retention and vasoconstriction central to ADHF.
CPAP and Bipap in HF
Short-term positive pressure is an important treatment for
pulmonary edema associated with ADHF.
positive airway pressure pushes the intra-alveolar
fluid out of the alveoli and creates more alveolar surface area for gas exchange.
positive intrathoracic pressure inherent in these therapies
acts to decrease venous return to the heart and reduce preload.
Systolic HF: Effects on CO
↓ Contractility + ↑ Compliance = ↑ Preload
↓ Contractility + ↑ Preload = a compensatory ↑ Afterload
↓ Contractility + ↑ Preload + ↑ Afterload = ↓ CO
Systolic HF
Ventricles become large, dilated, overloaded Increased LVEDV (increased preload) and LVEDP HFrEF (<40%) S3 gallop